Compare
Enanta Pharmaceuticals Inc vs Spero Therapeutics, Inc. vs Fortress Biotech, Inc. vs Kura Oncology, Inc.
| Latest fiscal year | Enanta Pharmaceuticals Inc ENTA | Spero Therapeutics, Inc. SPRO | Fortress Biotech, Inc. FBIO | Kura Oncology, Inc. KURA |
|---|---|---|---|---|
| Year ended | 2025-09-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $65.32M | $66.80M | $63.26M | $67.48M |
| Revenue growth (YoY) | -3.4% | +39.2% | +9.7% | +25.2% |
| Gross margin | n/a | n/a | 66.9% (computed) | n/a |
| Operating margin | -130.7% | 9.5% | -111.0% | -449.9% |
| Net margin | -125.4% | 12.8% | 10.8% | -412.9% |
| Net income | -$81.89M | $8.57M | $6.82M | -$278.67M |
| EPS (Diluted) | -$3.84 | $0.15 | -$0.07 | -$3.18 |
| Operating cash flow | -$19.27M | -$12.62M | -$65.78M | -$64.06M |
| Free cash flow | -$32.17M | n/a | n/a | -$70.70M |
| Cash & equivalents | $32.30M | $40.27M | $79.38M | $149.10M |
| Total assets | $280.73M | $68.92M | $185.55M | $738.36M |
| Total liabilities | $216.01M | $9.90M | $123.36M | $564.23M |
| Shareholders' equity | $64.72M | $59.02M | $49.87M | $174.13M |
| Return on year-end equity | -126.5% | 14.5% | 13.7% | -160.0% |
| Shares outstanding | 21.39M | 56.41M | 31.36M | 87.86M |
Revenue, most recent five fiscal years
| Fiscal year | Enanta Pharmaceuticals Inc | Spero Therapeutics, Inc. | Fortress Biotech, Inc. | Kura Oncology, Inc. |
|---|---|---|---|---|
| Latest | $65.32M Ended 2025-09-30 | $66.80M Ended 2025-12-31 | $63.26M Ended 2025-12-31 | $67.48M Ended 2025-12-31 |
| 1 year earlier | $67.64M Ended 2024-09-30 | $47.98M Ended 2024-12-31 | $57.67M Ended 2024-12-31 | $53.88M Ended 2024-12-31 |
| 2 years earlier | $79.20M Ended 2023-09-30 | $103.78M Ended 2023-12-31 | $84.51M Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | $86.16M Ended 2022-09-30 | $53.51M Ended 2022-12-31 | $75.74M Ended 2022-12-31 | n/a |
| 4 years earlier | $97.07M Ended 2021-09-30 | $18.26M Ended 2021-12-31 | $68.79M Ended 2021-12-31 | n/a |